Latest filing published 05 Jan 2017 for Aurinia Pharmaceuticals Inc., €101k.
Filing timeline
BuySaleInsider track record
Charles Rowland: trading record in brief
Charles Rowland appears in our data through filings on Aurinia Pharmaceuticals Inc. shares, published by SEC (Form 4). In total, 4 filings cover trades dated from 22 June 2016 to 5 January 2017.
No open-market sale appears; the market trades are 3 purchases worth €153k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Since January 2017: 3 purchases and no sales on the market.
A typical purchase (the median) is worth €51k. The 3 purchases reviewed show no overlap with other insiders buying the same stock within a month.
The record was last updated on 5 January 2017 with an open-market purchase (€101k) in Aurinia Pharmaceuticals Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Charles Rowland
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 65,714 shares@ CA$2.148520.3% of flowCommon SharesTSXSEDI:2937721Canonical exit: 4 Apr 2017 (T+90)
- 33,852 shares@ CA$2.133210.3% of flowCommon SharesTSXSEDI:2937716Canonical exit: 3 Apr 2017 (T+90)
- 434 shares@ CA$2.14850.1% of flowCommon SharesTSXSEDI:2937724Canonical exit: 5 Apr 2017 (T+90)
- 211,865 shares@ CA$2.3669.2% of flowCommon SharesTSXSEDI:2855495
4 of 4 declarations
